Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.07% to 1,371.60 Indian rupees Thursday, on what proved to be an ...
The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...
Dr. Reddy’s, a global pharmaceutical company with ties to Louisiana, will close its Shreveport manufacturing plant and ...
Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...
Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Welcome to the Dr Reddys Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a ...
5d
Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $15.49 and traded ...
Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active ...
Dr Reddy’s Laboratories shares has gained a total of 5.62% in the last one year, and 2.45% since the beginning of the year. Here are some of the stocks that may see significant price movement ...
Dr. Reddy's Laboratories Ltd. 500124 shares rallied 1.47% to 1,370.60 Indian rupees Wednesday, on what proved to be an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback